Abstract Number: 2830 • 2014 ACR/ARHP Annual Meeting
Progression to and Type of Orthopaedic Surgery in Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Background/Purpose: Juvenile-onset ankylosing spondylitis (JoAS) and adult-onset ankylosing spondylitis (AoAS) are subtypes of ankylosing spondylitis (AS) that may have different clinical outcome. We compared cohorts…Abstract Number: 2567 • 2014 ACR/ARHP Annual Meeting
Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab
Background/Purpose Using data from GO-RAISE, we analyzed correlations between serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels, radiographic progression and inflammation as…Abstract Number: 1519 • 2014 ACR/ARHP Annual Meeting
Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
Background/Purpose To evaluate the application of an acid dissociation procedure in monitoring patients with subtherapeutic serum concentrations of infliximab (IFX), adalimumab (ADL) and etanercept (ETN),…Abstract Number: 593 • 2014 ACR/ARHP Annual Meeting
The Clinimetric Outcomes of Two Bath Ankylosing Spondyltis Metrology Indices in Treatment with TNF-á Blockers
Background/Purpose Bath Ankylosing Spondyltis Metrology Index (BASMI) was developed to quantify the accurate axial status and to assess the clinical changes in spinal movement. The…Abstract Number: 538 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Physical Function and Quality of Life in Subjects with Active Ankylosing Spondylitis: Results of a Phase 3 Randomized, Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Background/Purpose: Ankylosing spondylitis (AS) can have a profound negative effect on an individual's physical functioning, health status and quality of life (QoL), affecting the ability…Abstract Number: 2831 • 2014 ACR/ARHP Annual Meeting
Development of New Radiographic Vertebral Fractures in Patients with Ankylosing Spondylitis during 4 Years of TNF-α Blocking Therapy: Results from the Glas Cohort
Background/Purpose: Previous studies have shown that the risk of vertebral fractures is increased in patients with ankylosing spondylitis (AS). Prospective longitudinal data about radiographic vertebral…Abstract Number: 2562 • 2014 ACR/ARHP Annual Meeting
The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis and ankylosing spondylitis; results from Turkbio Registry
Background/Purpose Three different anti–tumor necrosis factor α (anti-TNFα) drugs (infliximab, etanercept, and adalimumab) are approved for patients with rheumatoid arthritis (RA) and particular ankylosing spondylitis…Abstract Number: 1367 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Morbidity and Associated Risk Factors in Spanish Patients with Chronic Inflammatory Rheumatic Diseases Attending Rheumatology Clinics
Background/Purpose: The prevalence of cardiovascular disease (CVD) in chronic inflammatory rheumatic diseases (CIRD) is higher than in the general population. Recent studies have emphasized that…Abstract Number: 591 • 2014 ACR/ARHP Annual Meeting
The Fat Spondyloarthritis Spine Score (FASSS) Independently Predicts Radiographic Progression in Patients with Ankylosing Spondylitis
The Fat Spondyloarthritis Spine Score (FASSS) independently predicts radiographic progression in patients with ankylosing spondylitis. Background/Purpose Vertebral corner fat lesions have been shown to be…Abstract Number: 536 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a Phase 3, Randomized, Placebo-Controlled Trial with Subcutaneous Loading and Maintenance Dosing
Background/Purpose: Previous data indicate that interleukin (IL)-17, a key pro-inflammatory cytokine, might play a role in the pathogenesis of ankylosing spondylitis (AS). We assessed the…Abstract Number: 2832 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study
Background/Purpose For rheumatoid arthritis it is well established that co-medication (co-med) with methotrexate (MTX) increases the efficacy and drug survival of TNF inhibitors (TNFi), while…Abstract Number: 2564 • 2014 ACR/ARHP Annual Meeting
Ileocolonoscopic Findings in the Korean Patients with Ankylosing Spondylitis
Background/Purpose: The prevalence of concurrent Ankylosing spondylitis (AS) and inflammatory bowel disease, either Crohn's disease (CD) or Ulcerative colitis (UC), is estimated at 5-10%. Up…Abstract Number: 1285 • 2014 ACR/ARHP Annual Meeting
Prevalence of Risk Factors for Gastrointestinal Side Effects of Drugs for the Treatment of Pain in Rheumatic Diseases and the Provision of Gastroprotective Treatment – Results of a Large Non-Intervention Study
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the long established first-line treatment for the management of pain associated with rheumatic diseases but carry a risk of…Abstract Number: 589 • 2014 ACR/ARHP Annual Meeting
Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa
Background/Purpose The ASAS axial SpA classification criteria was published in 2009 but so far there has been limited research on axial SpA patients in clinical…Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 57
- Next Page »